Intuitive Surgical has a robust long-term observe file, however has not had a terrific YTD or one-year efficiency. The Each day Breakdown digs in. Enthusiastic about extra Deep Dive content material? Take a look at our newest analysis.
Deep Dive
Regardless of a $160 billion market cap and a 556% return over the past decade, Intuitive Surgical should fly beneath the radar for a lot of traders. That stated, shares are down about 25% from their highs and have fallen nearly 15% over the previous yr.
The corporate develops applied sciences that assist physicians carry out minimally invasive procedures worldwide. Its key merchandise embody the da Vinci Surgical System for advanced surgical procedures and the Ion endoluminal system for lung biopsies. The corporate additionally gives devices, coaching, companies, and digital instruments to help robotic surgical procedure applications.
For years, Intuitive Surgical has been a gentle operator throughout the healthcare house. Like many others although, it noticed some lumpiness in its enterprise from 2020 to 2022. Since then, it’s been comparatively clean crusing for earnings, income, and recurring income:
Future Development Projections
Wanting forward, analysts count on fairly constant outcomes of Intuitive Surgical, with anticipated annual earnings and income development within the 13% and 16% vary. In keeping with Bloomberg, analysts mission the next:
Earnings Development: 15.8% in 2026, 13.6% in 2027, and 13.8% in 2028
Income Development: 16.4% in 2026, 13.2% in 2027, and 13.1% in 2028
Analysts at the moment have a consensus value goal of ~$576 on ISRG inventory, implying about 27% upside to right this moment’s inventory value.
Need to obtain these insights straight to your inbox?
Enroll right here
Diving Deeper — Valuation
Mid-teen development charges are very stable and characterize regular enlargement. Nevertheless, there could also be some hesitancy from traders to pay up for ISRG inventory for development that’s sturdy, however not essentially out of this world. That’s the place valuation-focused traders might get hung up on Intuitive Surgical.
On the one hand, ISRG is buying and selling at its lowest ahead price-to-earnings ratio in nearly three years (white line). Nevertheless, it’s nonetheless above the valuation zone of 38x or decrease, which has marked a trough since 2019. On a ahead price-to-FCF foundation (blue line), the inventory is close to a trough zone of roughly 33x. On the finish of the day although, some may nonetheless argue that this valuation is an excessive amount of for mid-teen development.
Dangers
Key dangers for Intuitive Surgical embody its heavy reliance on da Vinci process development, which will be pressured by hospital staffing points, elective-surgery traits, and tighter hospital budgets. The corporate additionally faces execution danger across the da Vinci 5 improve cycle, rising competitors in surgical robotics, tariff and margin pressures, and China-specific dangers tied to pricing, reimbursement, quotas, and native rivals. In the meantime, slower adoption of newer platforms like Ion, potential regulatory or issues of safety, and ISRG’s premium valuation depart little room for disappointment.
The Backside Line
Intuitive Surgical has turn into a blue-chip inventory throughout the medical gadget business. Nevertheless, shares have struggled much less as a result of the enterprise is damaged and extra as a result of the inventory was priced for perfection. Expectations have been sky-high, margins have been beneath scrutiny, and traders are questioning whether or not development can maintain justifying the premium a number of.
Because the inventory value has come down, traders at the moment are questioning whether or not a long-term alternative is in entrance of them or if it’s a crimson warning flag to remain away.
Disclaimer:
Please be aware that on account of market volatility, a number of the costs might have already been reached and eventualities performed out.
